AGC Biologics, a leading pharmaceutical company based in Denmark, has recently announced plans to expand production capacity for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects at the company's Heidelberg location.
By adding an extra GMP manufacturing line, AGC Biologics is increasing its current 100L and 1,000L manufacturing capacities for various biologics projects.
Other additions include a new GMP cleanroom for development and production of mRNA, a novel process development lab for microbial protein and cell and gene therapy (C>) projects, and increased warehousing capacity.
With these expanded capabilities, AGC Biologics will be able to fulfil the rising demands of the C> industry. The additional capabilities of the plant will be completely operational in 2023.
AGC Biologics’ Chief Executive Officer, Patricio Massera says that this investment supports the foray into the mRNA space while solidifying the existing pDNA capabilities. The firm is focused on ensuring that its facilities worldwide offer innovative services that meet the needs of therapeutics developers, as the global pDNA and mRNA markets are experiencing record growth.
Dieter Kramer, AGC Biologics' Heidelberg Site Head, stated that these new facilities would help reinforce the Heidelberg facility. The firm looks forward to this site as it will have a stronger influence on the services that AGC Biologics provides to the industry.
This is the latest in a series of investments made by AGC Biologics to enhance its offerings and global footprint this year. In August, AGC Biologics began work on a new multipurpose facility in Copenhagen, Denmark, that will expand the company's global capacity.
The announcement comes about a month after AGC Biologics completed the successful acquisition of the Longmont, CO. plant, which helped the business expand its C> competencies footprint in the United States.
AGC Biologics also extended its Cell and Gene Therapy Facility in Milan, Italy, earlier this year, adding more capacity and viral vector suspension proficiencies.